Christopher L Case
4 Papers
Christopher L Case is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
Katherine V. Houser,Martin R. Gaudinski,Myra Happe,Sandeep Narpala,Raffaello Verardi,Edward K Sarfo,Angela R. Corrigan,Richard Wu,Ro Shauna S Rothwell,Laura Novik,Cynthia S. Hendel,Ingelise J. Gordon,Nina M. Berkowitz,Cora Trelles Cartagena,Alicia T. Widge,Emily E. Coates,Larisa Strom,Somia P. Hickman,Michelle Conan-Cibotti,Sandra Vazquez,Olga Trofymenko,Sarah H. Plummer,Judith A Stein,Christopher L Case,Martha Nason,Andrea Biju,Danealle K. Parchment,Anita Changela,Cheng Cheng,Hongying Duan,Hui Geng,I-Ting Teng,Tongqing Zhou,Sarah O’Connell,Christopher Barry,Kevin Carlton,Jason G. D. Gall,Britta Flach,Nicole A. Doria-Rose,Barney S. Graham,Richard A. Koup,Adrian B. McDermott,John R. Mascola,Peter D. Kwong,Julie E. Ledgerwood +44 more
TL;DR: Trimer 4571 (BG505 DS-SOSIP) adjuvanted with aluminum hydroxide (alum) was evaluated in a phase I, randomized, open-label, dose-escalation trial at the National Institutes of Health Clinical Center in Bethesda, MD, USA as mentioned in this paper .
22
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Emily E. Coates,Srilatha Edupuganti,Grace L. Chen,Myra Happe,Larisa Strom,Alicia T. Widge,M. Florez,Josephine H. Cox,Ingelise J. Gordon,Sarah Plummer,Abidemi Ola,Galina Yamshchikov,Charla Andrews,Sharon Curate-Ingram,Patricia Morgan,Shashi Nagar,Matthew H. Collins,Amy Bray,Thuy An Nguyen,Judith A Stein,Christopher L Case,Florence Kaltovich,Diane Wycuff,C. Liang,Kevin Carlton,Sandra Vazquez,John R. Mascola,Julie E. Ledgerwood +27 more
- 01 May 2022
TL;DR: The favourable safety profile and neutralising antibody responses, along with pressing public health need, support further evaluation of the WEVEE VLP vaccine in advanced-phase clinical trials.
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults
Richard L. Wu,Katherine V. Houser,Martin R. Gaudinski,Alicia T. Widge,Seemal F Awan,Cristina Carter,LaSonji A. Holman,Jamie Saunders,Cynthia S. Hendel,Aba Mensima Eshun,William Whalen,Xiaolin Wang,Anita Arthur,Jennifer E Cunningham,Allison Beck,Joseph P. Casazza,Galina Yamshchikov,Ro Shauna S Rothwell,Larisa Strom,Tejaswi Dittakavi,Myra Happe,Somia P. Hickman,Michelle Conan-Cibotti,Kevin Carlton,Lily Zhang,Yunda Huang,Edmund V Capparelli,Bob C Lin,Sarah O’Connell,Britta Flach,Robert T. Bailer,Sandeep Narpala,L. R. Serebryannyy,Adrian B McDermott,Frank J. Arnold,Jason G. Gall,Sandra Vazquez,Nina M. Berkowitz,Ingelise J. Gordon,Grace L Chen,P. Kwong,Jinghe Huang,Theodore C. Pierson,Mark Connors,John R. Mascola,Tongqing Zhou,Nicole A. Doria-Rose,Richard A. Koup,Lesia K. Dropulic,Julie E. Ledgerwood,Barney S. Graham,Emily E. Coates,Krisha McKee,Mark K. Louder,Amarendra Pegu,Floreliz Mendoza,Pamela Costner,Laura Novik,Kathy Zephir,Brenda Larkin,Sarah H. Plummer,Abidemi Ola,Preeti Apte,Cora Trelles Cartagena,Renunda Dyer,Pernell Williams,Shinyi Telscher,Colin Tran,Olga Vasilenko,Karen Parker,Priya Kamath,Jennifer Phipps,Olympia Hotobah-During,Jackie Stephens,Justine Jones,Jumoke Gbadebo,Catina Evans,Sandra Sitar,Christian Buettner,Sana Waheed,Maria Burgos Florez,Eugeania Burch,Lam Ngoc Quynh Le,Olga Trofymenko,Patricia Morgan,Mark O'Callahan,Ellie Seo,Lauren Brant,Iris Pittman,Katherine Brooks,Martha Nason,Ana Villa-Ortega,Thuy Nguyen,Lucio Gama,Florence Kaltovich,Jason Sands,Christopher L Case,Judith A Stein +97 more
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
Katherine V. Houser,Grace L. Chen,Cristina Carter,Michelle C. Crank,Thuy An Nguyen,Maria Burgos Florez,Nina M. Berkowitz,Floreliz Mendoza,Cynthia S. Hendel,Ingelise J. Gordon,Emily E. Coates,Sandra Vazquez,Judith A Stein,Christopher L Case,Heather Lawlor,Kevin Carlton,Martin R. Gaudinski,Larisa Strom,Amelia R. Hofstetter,C. Jason Liang,Sandeep Narpala,C. H. Hatcher,Rebecca A. Gillespie,Adrian Creanga,Masaru Kanekiyo,Julie E. Raab,Sarah F. Andrews,Yi Zhang,Eun Sung Yang,Lingshu Wang,Kwanyee Leung,Wing Pui Kong,Alec W. Freyn,Raffael Nachbagauer,Peter Palese,Robert T. Bailer,Adrian B. McDermott,Richard A. Koup,Jason G. D. Gall,Frank J. Arnold,John R. Mascola,Barney S. Graham,Julie E. Ledgerwood,Joseph P. Casazza,LaSonji A. Holman,Abidemi Ola,Pamela Costner,Jennifer Cunningham,Brenda Larkin,Laura Novik,Jamie G. Saunders,William Whalen,Xiaolin Wang,Aba Mensima Eshun,Alison Taylor,K. C. Cheng,Carolyn M. Laurencot,Josephine H. Cox,Sandra Sitar,Lam Le,Iris Pittman,Olga Vasilenko,Ro Shauna S Rothwell,Galina Yamshchikov,Eugenia Burch,Somia P. Hickman,Olga Trofymenko,Catina R. Boyd,Preeti Apte,Cora Trelles Cartagena,Renunda Hicks,Pernell Williams,Zana Blaku,Colin Tran +73 more
TL;DR: In this paper , a first-in-human, randomized, open-label, phase 1 clinical trial was conducted to evaluate a novel ferritin (H2HA-Ferritin) nanoparticle influenza vaccine platform.